Remote Ischemic Preconditioning in High-risk Cardiovascular Surgery Patients: A Randomized-controlled Trial

Area of Science:

• Cardiology
• Vascular Surgery
• Critical Care Medicine

Background:

• Remote ischemic preconditioning (RIPC) shows potential in reducing biomarkers of ischemic injury post-cardiovascular surgery.
• Clinical efficacy of RIPC on patient outcomes after cardiovascular surgery remains uncertain.

Purpose of the Study:

• To evaluate the impact of RIPC on clinical outcomes in patients undergoing high-risk cardiac or vascular surgery.
• To determine if RIPC reduces the incidence of major adverse events following cardiovascular procedures.

Main Methods:

• A blinded, randomized controlled trial involving 436 patients undergoing cardiac or vascular surgery.
• Intervention group received 3 cycles of RIPC; control group received a sham intervention.
• Primary endpoint was a composite of mortality, myocardial infarction, stroke, renal failure, respiratory failure, and low cardiac output syndrome.

Main Results:

• No significant difference in the composite outcome between RIPC (32%) and control (34%) groups (RR 0.94 [0.72-1.24]).
• Individual components of the composite outcome, troponin-I levels, and length of hospital stay were similar between groups.
• RIPC demonstrated no beneficial effect on clinical outcomes in the studied patient population.

Conclusions:

• Remote ischemic preconditioning does not appear to offer clinical benefits for patients undergoing cardiovascular surgery.
• Further research may be needed to explore potential alternative applications or patient subgroups for RIPC.